Drug Description in Trials / DrugBank / KEGG DRUG /


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
10.5 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
21 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
31mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
42mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
55 mg Montelukast1件: Montelukast2件: D00529 ,
D08229
1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98
6AK002----1件: 98
7Allergen----1件: 98
8Allergy immunotherapy (allergy shots)----1件: 98
9APD334----5件: 93, 96, 97, 98, 269
10APT-1011----1件: 98
11APT-1011 - 3 mg----1件: 98
12AR401959 L-arginine1件: Arginine1件: D02982 --3件: 96, 97, 98
13Arginine1件: Arginine1件: D02982 --11件: 46, 58, 67, 78, 96, 97, 98, 113, 210, 251, 299
14Barium1件: Barium---3件: 2, 19, 98
15Beclomethasone dipropionate1件: Beclomethasone dipropionate2件: D00689 ,
D07495
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 97, 98
16Behavioral: six-foods elimination diet----1件: 98
17Benralizumab1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
18Bethanechol1件: Bethanechol1件: D01000 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬
13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 98
19BT----4件: 6, 96, 97, 98
20BT-11 1000mg----3件: 96, 97, 98
21BT-11 500mg----1件: 98
22BUDESONIDE1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬9件: 66, 93, 94, 95, 96, 97, 98, 228, 299
23Budesonide 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
24Budesonide 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
25Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
26Budesonide 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
27Budesonide 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
28Budesonide 1 mg orodispersible tablets (BUL 1 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
29Budesonide 1mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
30Budesonide 2 mg orodispersible tablets (BUL 2 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
31Budesonide [0.4mg/ml] viscous suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
32Budesonide oral suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
33Budesonide oral suspension [0.2 mg/ml]1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
34Budesonide plus Prevacid1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
35BUET 0.5 mg----1件: 98
36BUET 1 mg----1件: 98
37BUET 1mg----1件: 98
38BUET 2mg----1件: 98
39BUL 0.5 mg----1件: 98
40BUL 1 mg----1件: 98
41BUU 0.4mg/ml----1件: 98
42CALY-002----1件: 98
43CC----14件: 13, 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271
44CC-93538----1件: 98
45Cendakimab----1件: 98
46Citalopram1件: Citalopram2件: D00822 ,
D07704
1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬7件: 6, 8, 13, 18, 46, 98, 127
47Compressa effervescente 0,5 mg di budesonide per uso orodispersibile1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
48Compressa effervescente 1 mg di budesonide per uso orodispersibile1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
49Cortisol1件: Hydrocortisone1件: D00088 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 81, 98
50Cromolyn1件: Cromoglicic acid2件: D00526 ,
D07753
--3件: 2, 85, 98
51Dexlansoprazole1件: Dexlansoprazole1件: D08903 2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
52Diagnostic Test: Barium Esophagram1件: Barium---1件: 98
53Diagnostic Test: Bone Mineral Density (DEXA) scan----1件: 98
54Diagnostic Test: Cortisol level1件: Hydrocortisone1件: D00088 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
55Diagnostic Test: Endoscopy while on study drug----1件: 98
56Diagnostic Test: Gastrointestinal Quality of Life index----1件: 98
57Diagnostic Test: Height measurement----1件: 98
58Diagnostic Test: High-resolution manometry----1件: 98
59Diagnostic Test: Physical Examination and Questionnaires----1件: 98
60Diagnostic Test: Retrospective evaluation of endoscopy prior to study drug----1件: 98
61Diagnostic Test: Serum biomarkers----1件: 98
62Diagnostic Test: Vitamin D Measurement1件: Vitamin D---1件: 98
63Dupilumab1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬4件: 51, 98, 160, 162
64Dupilumab (blinded)1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
65Dupilumab (open-label)1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
66Dupixent1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬3件: 98, 160, 162
67E0E food introduction-2nd----1件: 98
68EoE food introduction-1st----1件: 98
69EoE Food introduction-3rd dose----1件: 98
70ESO-101----1件: 98
71Esomeprazole1件: Esomeprazole4件: D01984 ,
D04056 ,
D07917 ,
D09339
2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬8件: 13, 46, 86, 98, 107, 113, 298, 299
72EsophaCap----1件: 98
73Esophageal dilation----1件: 98
74Esophagogastroduodenoscopy----1件: 98
75Etrasimod1件: Etrasimod1件: D10930 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98
76Etrasimod L-arginine2件: Arginine,
Etrasimod
2件: D02982 ,
D10930
5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98
77EUR-1100----1件: 98
78Famotidine1件: Famotidine1件: D00318 1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬6件: 6, 46, 86, 98, 107, 300
79Fasenra1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
80Florence 30 µg/mL----1件: 98
81Florence 60 µg/mL----1件: 98
82Florence 90 µg/mL----1件: 98
83Flovent----1件: 98
84Fluticasone1件: Fluticasone1件: D07981 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 98, 228, 299
85Fluticasone MDI1件: Fluticasone1件: D07981 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
86FLUTICASONE PROPIONATE2件: Fluticasone,
Fluticasone propionate
2件: D01708 ,
D07981
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 228
87Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)2件: Fluticasone,
Fluticasone propionate
2件: D01708 ,
D07981
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
88Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)2件: Fluticasone,
Fluticasone propionate
2件: D01708 ,
D07981
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
89Fluticasone Propionate, USP2件: Fluticasone,
Fluticasone propionate
2件: D01708 ,
D07981
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
90Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318
91High dose budesonide suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
92High dose budesonide tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
93Honey1件: Honey1件: D06776 --3件: 57, 98, 299
94Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
95Inhaled/swallowed budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
96Intraluminal Impedance----1件: 98
97Intubated with Propofol (IP)1件: Propofol1件: D00549 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 98
98Intubated with Sevoflurane (IS)1件: Sevoflurane1件: D00547 --1件: 98
99IRL201104----1件: 98
100Jorveza1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
101Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
102Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
103Jorveza 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
104Jorveza 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
105Lansoprazole1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬7件: 63, 71, 85, 98, 166, 222, 299
106Lirentelimab1件: Lirentelimab1件: D11906 1件: SIGLEC8 💬-1件: 98
107Lirentelimab (AK002)1件: Lirentelimab1件: D11906 1件: SIGLEC8 💬-1件: 98
108Loratadine1件: Loratadine1件: D00364 1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬4件: 13, 46, 89, 98
109Losartan1件: Losartan2件: D00357 ,
D08146
1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
110LOSARTAN POTASSIUM2件: Losartan,
Potassium
3件: D00357 ,
D08146 ,
D08403
1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 36, 98, 167, 179, 215
111Low dose budesonide tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
112MEDI-563----5件: 44, 45, 98, 162, 299
113MEPOLIZUMAB1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬4件: 44, 45, 98, 162
114Mepolizumab 100 mg1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98
115Mepolizumab 300 mg1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98
116Milk1件: Cow milk---2件: 98, 210
117Mometasone1件: Mometasone3件: D00690 ,
D03325 ,
D08227
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
118MOMETASONE FUROATE1件: Mometasone3件: D00690 ,
D03325 ,
D08227
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
119MONITOR1件: Methamidophos---20件: 2, 11, 13, 19, 28, 46, 49, 58, 65, 70, 81, 85, 86, 98, 113, 118, 129, 298, 299, 300
120Montelukast1件: Montelukast2件: D00529 ,
D08229
1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬8件: 6, 13, 46, 61, 63, 85, 98, 228
121Montelukast/ Singulair1件: Montelukast2件: D00529 ,
D08229
1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98
122Nasonex----1件: 98
123NIOX MINO® Airway Inflammation Monitor1件: Methamidophos---1件: 98
124Nitric Oxide1件: Nitric Oxide1件: D00074 --8件: 46, 85, 86, 98, 210, 251, 294, 299
125Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy----1件: 98
126OC000459----1件: 98
127OMALIZUMAB1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299
128Omeprazole1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261
2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
129Omeprazole 20 MG Oral Tablet1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261
2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
130Omeprazole 20mg BID1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261
2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
131Oral Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
132Oral Budesonide Suspension (MB-9)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
133Oral Budesonide Suspension (OBS)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
134Oral cromolyn sodium1件: Cromoglicic acid2件: D00526 ,
D07753
--1件: 98
135Oral Viscous Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
136Oral Viscous Budesonide (OVB)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
137Other: 1 Food Elimination Diet----1件: 98
138Other: 1 Food Elimination Diet Therapy----1件: 98
139Other: 4 Food Elimination Diet----1件: 98
140Other: 4 Food Elimination Diet (post 1FED failure)----1件: 98
141Other: 6 Food Elimination Diet (after 1FED failure)----1件: 98
142Other: 6 Food Elimination Diet Therapy----1件: 98
143Other: Antigen (wheat base soy sauce) spray1件: Wheat1件: D06902 --1件: 98
144Other: Assessment of medication compliance----1件: 98
145Other: D-xylose1件: Xylose1件: D06346 --1件: 98
146Other: Elimination diet----1件: 98
147Other: Honey1件: Honey1件: D06776 --1件: 98
148Other: Medication Compliance Phone Call----1件: 98
149Other: Oral Nitric Oxide testing1件: Nitric Oxide1件: D00074 --1件: 98
150Other: Saline----8件: 2, 6, 46, 97, 98, 256, 274, 301
151Other: Symptom Survey----1件: 98
152Other: Xanthan Gum1件: Xanthan gum1件: D06333 --1件: 98
153Potassium1件: Potassium1件: D08403 --12件: 36, 46, 66, 67, 88, 94, 98, 115, 167, 179, 215, 235
154PROPOFOL1件: Propofol1件: D00549 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬9件: 6, 21, 22, 34, 46, 70, 84, 98, 296
155QAX576----4件: 51, 85, 96, 98
156Radiation: Computerized Tomography scan----1件: 98
157Radiation: Esophageal Barium Xray1件: Barium---1件: 98
158Radiation: Planar Images----1件: 98
159Radiation: Single Photon Emission Computed Tomography scans----1件: 98
160Reslizumab1件: Reslizumab1件: D08985 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬2件: 44, 98
161RPC4046----1件: 98
162SB-240563----3件: 44, 45, 98
163SCH55700----1件: 98
164Sevoflurane1件: Sevoflurane1件: D00547 --7件: 6, 21, 22, 34, 98, 225, 296
165Sirolimus1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬36件: 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331
166Steroid and Proton Pump Inhibitor Therapy----1件: 98
167Sucralfate1件: Sucralfate1件: D00446 --1件: 98
168Swallowed fluticasone1件: Fluticasone1件: D07981 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
169Technetium Tc 99m1件: Technetium Tc-99m---2件: 46, 98
170Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
171Viaskin Milk 500 mcg1件: Cow milk---1件: 98
172Viscous/swallowed budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
173Vitamin D1件: Vitamin D---24件: 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299
174Vonoprazan1件: Vonoprazan1件: D11784 2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬2件: 63, 98
175Wheat1件: Wheat1件: D06902 --3件: 6, 98, 266
176Xanthan gum1件: Xanthan gum1件: D06333 --1件: 98
177Xylose1件: Xylose1件: D06346 --1件: 98
178Zofran - no intubation----1件: 98